Benzinga | Nov 12, 2020 04:57AM EST

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $191

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $173 to $191.